ImCheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute in Marseille (France). The biotech company is developing innovative antibody therapeutics in the field of immuno-oncology, based on scientific assets originating from the pioneering work of Prof. Daniel Olive.
When ambition meets ambition
ImCheck Therapeutics is an emerging player in the field of cancer and auto-immune immunotherapies that focuses on the development of first-in-class antibodies that activate the immune system against different cancer types. Gimv strongly believes in the company because of the game-changing potential of ImCheck’s development candidates for the treatment of cancer.
Together, we build a leading company
The funds will be used to advance its lead candidates towards clinical development, as well as to progress its discovery programs.
Our previous investments in Topas Therapeutics, G-Therapeutics, Endostim, Spineart and Breath Therapeutics will allow us to help ImCheck Therapeutics in realizing its ambitions.